Skip to main content
OpenTrials
Completed

NCT Number: NCT07101783

A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity

The study is testing the new medicine NNC0662-0419 in people living with overweight or obesity. The purpose of the study is to look into the amount of the new medicine NNC0662-0419 in participants blood after one dose. And also look into how safe and how well the study medicine is tolerated in people living with overweight or obesity. NNC0662-0419 is a new medicine which cannot be prescribed by doctors. NNC0662-0419 is currently being tested in humans and the dose participants will receive has been found safe and tolerable. Participants will get a single dose of NNC0662-0419 given by study staff as a single injection under participants skin. Like all medicines, the study medicine may have side effects. The study will last up to 2 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Altasciences Clinical LA, Inc.

Cypress, California, 90630, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female (sex at birth) Japanese, Chinese or non-Asian participants (all self-reported).
  • For Japanese participants: both parents of Japanese descent.
  • For Chinese participants: both parents of Chinese descent.
  • For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
  • Age 18-55 years (both inclusive) at the time of signing the informed consent.
  • Body mass index (BMI) between 24.0 and 34.9 kilogram per square meter (kg/m^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

  • Known a* or suspected hypersensitivity to study intervention(s) or related products.
  • Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.
  • 2nd or 3rd degree atrioventricular-block, prolongation of the QRS complex over 120 millisecond (msec), or of the corrected QT interval by Fridericia (QTcF) calculation over 450 msec (females) or 430 msec (males), or any other clinically significant abnormal electrocardiogram (ECG) results as judged by the investigator, at screening.
  • Glycated haemoglobin (HbA1c) greater than or equal to >= 6.5percent (%) (48 millimoles per liter [mmol/mol]) at screening.
  • Calcitonin >= 50 nanogram per liter (ng/L) at screening. a* - As declared by the participant or reported in the medical records.

Treatment and study plan

NNC0662-0419

Drug

Participants will receive NNC0662-0419 subcutaneously.

Primary outcomes

  1. AUC; The area under the NNC0662-0419 plasma concentration-time curve

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 29)

    Measured in hours*nanomoles per liter (h*nmol/L).

Secondary outcomes

  1. Cmax; The maximum plasma concentration of NNC0662-0419

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 29)

    Measured in nanomoles per liter (nmol/L).

  2. Number of treatment-emergent adverse events (TEAEs)

    Time frame: From time of dosing on Day 1 until completion of the end of study visit (Day 29)

    Measured as number of events.

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

Investigation of Pharmacokinetic Properties of Single Doses of NNC0662-0419 in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 3, 2025
Registry last updated
Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.